I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Vasoplegia is a term that describes excessive loss of vascular muscle tone leading to a distributive shock status. Vasoplegic syndrome (VS) after cardiac surgery is a condition characterized by hypotension increased cardiac index (CI), low systemic vascular resistance (SVR), normal filling pressures, and increased vasopressor and fluid requirements.\[[@ref1]\] The syndrome is reported with an incidence ranging between 5% and 25%.\[[@ref2]\] The exact mechanism of VS is unknown; it is suggested to be multifactorial, hemodilution, baroreceptor reflexes, and complement activation are involved. However, VS is associated with a systemic inflammatory response that results in endothelial dysfunction and production of nitric oxide (NO) from L-arginine by polymorphonuclear blood cells in response to the enzyme inducible NO synthase. NO in turn stimulates the production of cyclic guanosine monophosphate (cGMP) which is the final messenger of the NO pathway responsible for vasoplegia. cGMP formation is dependent on the enzyme guanylate cyclase (GC). Excessive formation of NO and cGMP is related to profound vasodilatation, myocardial depression, and decreased response to catecholamines.\[[@ref3]\]

Traditional treatment for VS would be fluid resuscitation and the use of vasopressor agents, such as phenylephrine, norepinephrine, and vasopressin. As an alternative, methylene blue (MB) was proposed because it antagonizes the effect of NO and other vasodilators in the endothelium and vascular smooth muscle by binding to GC and blocking cGMP action in vascular smooth muscle.\[[@ref4]\] Using MB to counteract excessive vasodilatation has been described in different settings: septic shock,\[[@ref5][@ref6][@ref7]\] endocarditis,\[[@ref8]\] transplant,\[[@ref9]\] and protamine reaction.\[[@ref10]\] The treatment of vasoplegic manifestation after cardiopulmonary bypass (CPB) using MB administration has been suggested in both adult\[[@ref11][@ref12][@ref13][@ref14][@ref15]\] and pediatric cardiac surgery.\[[@ref16][@ref17]\]

The aim of this study is to evaluate the effectiveness and outcome of MB therapy in VS after cardiac surgery in adults.

P[ATIENTS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
================================================

After approval by Institutional research center and ethics committees, the study was conducted in cardiac surgical Intensive Care Unit (CSICU), (24 beds postcardiac ICU), King Faisal Heart Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Being retrospective chart review study, consent was waived by the ethical committee.

Inclusion criteria {#sec2-1}
------------------

All adult patients who had cardiac surgery between January 2010 and May 2015 and received MB for VS during their stay in CSICU were included in the study.

VS was defined by the presence of all the following criteria:

Hypotension (mean arterial pressure \[MAP\] \<50 mm Hg)Low filling pressure (\[central venous pressure\] CVP \<5 mm Hg and pulmonary capillary wedge pressure (PCWP) \<10 mm Hg)CI \>2.5 L/min/m^2^Low resistance: SVR \<800 dyn. s/cm^5^, or SVR index (SVRI) \<1500 dyn. s/cm^5^/m^2^Vasoactive inotropic score (VIS)\[[@ref18]\] ≥50.

VIS = Dopamine dose (μg/kg/min) + Dobutamine dose (μg/kg/min) + 100 × epinephrine dose (μg/kg/min) + 100 × Norepinephrine dose (μg/kg/min) + 10,000 × Vasopressin dose (U/kg/min) + 10 × Milrinone dose (μg/kg/min).

Exclusion criteria {#sec2-2}
------------------

Age \<18 yearsPregnant womenDecision of care limitationFailure to insert pulmonary artery catheter (PAC)Cardiogenic shock\[[@ref19]\]Patients with a left ventricular ejection fraction (LVEF) \<35%Septic shock.\[[@ref20]\]

Study design {#sec2-3}
------------

Retrospectively, the medical records of all patients who had symptoms and signs suggestive of VS were reviewed. Before 2010, the use of MB for VS was not popular in our institution. However, since then many intensivist and anesthesiologists starts to use it until it became almost the gold standard for all patients who had VS after cardiac surgery and failed to respond to vasopressors. All patients who received MB from January 2010 to May 2015 were included in this study. Another group containing the patients who suffered from the signs and symptoms of VS during the period of 2004 till 2009 were included and acted as historical control. To reduce the confounding effects, a propensity score was created and both groups were matched accordingly.

Postoperative management in cardiac surgical intensive care {#sec2-4}
-----------------------------------------------------------

If VS is suspected despite adequate fluid resuscitation and adequate doses of vasopressors, a thermodilution PAC was inserted (if not present) to confirm the diagnosis and help further management. Once VS is confirmed, norepinephrine infusion was started (if not yet) and adjusted according to the cardiac output (CO) and SVR. Failure to respond to norepinephrine alone will usually initiate the use of other vasopressors as vasopressin/epinephrine or both. Increasing vasopressor support to a VIS is ≥50, initiated the use of MB. A bolus dose of 2 mg/kg of MB over 30 min was started and followed by 0.5--1 mg/kg/h if needed. Invasive MAP, mean pulmonary arterial pressure, CVP, PCWP, CO, CI, SVR, SVRI, heart rate, arterial oxygen saturation, respiratory rate (RR), core temperature, and electrocardiography were recorded. IV MB infusion was discontinued once the patient had improvement in hemodynamic parameters.

Data collection {#sec2-5}
---------------

Data collected included demographic (age, sex, weight, body mass index \[BMI\]); premorbid conditions and risk factors (diabetes mellitus \[DM\], hypertension \[HTN\], smoking, renal function including creatinine level, dialysis and cerebrovascular accidents \[CVA\]); the preoperative cardiac conditions (LVEF and ischemic heart disease \[IHD\]); preoperative medications (angiotensin converting enzyme inhibitor \[ACEI\], beta blockers, anticoagulant, and antiplatelets); admission laboratory values \[hemoglobin, prothrombin time (PT), activated partial thromboplastin time, (INR), electrolyte levels, bilirubin level, white blood counts, and platelet counts\]. Information needed to calculate European System for Cardiac Operative Risk Evaluation II (Euro-SCORE II)\[[@ref21]\] was obtained for each patient. Operative data included previous cardiac surgery, priority of the cardiac surgery, CPB time, cross-clamp time (X clamp) time, type of the procedure, need and type of mechanical circulatory support. Postoperatively, maximum VIS, arterial blood gases, urine output and chest tube bleeding were recorded hourly. The data collected was entered into an Excel database designed for the study.

End-points {#sec2-6}
----------

To compare the two groups regarding:

Time to improvement of vasoplegia (Ti) defined as: Time from admission till the improvement of hemodynamic parameters (MAP, CVP, PCWP, CI, and SVRI) and decrease in VIS by 50% or more from the maximum valuePostoperative Complications: Renal failure,\[[@ref22]\] need for dialysis, respiratory complications (ARDS),\[[@ref23]\] duration of mechanical ventilation (MV), reintubation, CVA,\[[@ref24]\] duration of inotropic support, readmission to CSICU, and reoperation.CSICU, hospital length of stay (LOS) andMortality at 30 days.

Statistical analysis {#sec2-7}
--------------------

Descriptive statistics for the continuous variables are reported as mean ± standard deviation, and categorical variables are summarized as frequencies and percentages. Continuous variables are compared by Student\'s independent *t*-test; while categorical variables are compared by Chi-square or Fisher\'s exact test. Demographic date (age, sex, and BMI), preoperative comorbidities (DM, HTN, smoking, IHD, dialysis, and CVA), operative risks (LVEF, Euro-SCORE II, CPB, and X clamp), and postoperative hemodynamic status (MAP, CVP, PCWP, CO, CI, and VIS) were used in generation of propensity score through logistic regression. The level of significance was set at 0.25. Then patients were matched 1:1 with the nearest neighbor according to propensity scores. Then, all analyses were performed in this matched cohort. Kaplan--Meir survival curve was estimated, and comparison between overall survivals in the two groups was done using log-rank test. The level of significance is set at *P* \< 0.05. Statistical analyses of data were done using the software package IBM Statistical Package for the Social Science (SPSS), Chicago, Illinois, USA version 23 for Microsoft Window.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

All adult patients who had cardiac surgery between 1^st^ of January 2010 and 31^st^ of May 2015 were screened for those who had symptoms and signs suggestive of VS. Fifty-one patients identified, three were excluded due to confirmed septic shock association, one due to failure to insert PAC secondary to superior vena cava thrombosis, 12 patients responded to vasopressor/inotropes, and 35 received MB for unresponsive VS. These 12 patients who responded to vasopressors could have acted as controls for the treatment group. However, although fulfilled the inclusion criteria of VS according to definition used in this study, they had a statistically significant better hemodynamic parameters and could not be matched to MB patients. We thought that this will imply effects on the interpretation of the results. For this, we preferred to have a historical control group from an equal period of time (2004 till 2009) where the use of MB was not familiar in our CSICU. Revising the medical charts, 57 patients were identified to have VS. Twenty-eight patients in MB group were successfully matched to patients in the control group in 1:1 ratio using the propensity score according to [Figure 1](#F1){ref-type="fig"}.

![Patients included in the study](IJCCM-22-168-g001){#F1}

There was no statistical significant difference between the two groups regarding demographic, preoperative risks, preoperative cardiac condition, preoperative medications, operative data, admission laboratory results, hemodynamics, and VIS before start of MB \[Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}\]. The mean time from admission to start the MB was 4.3 ± 1.4 h. Five patients received only bolus dose of MB while the other 23 patients received both bolus and IV infusion. The mean time for MB IV infusion was 4.7 ± 0.9 h.

###### 

Descriptive data of both groups

![](IJCCM-22-168-g002)

###### 

Laboratory results on admission from OR to cardiac surgical Intensive Care Unit

![](IJCCM-22-168-g003)

###### 

Hemodynamics before methylene blue

![](IJCCM-22-168-g004)

The Ti and time till complete discontinuation of vasopressors were statistically significant less in MB group compared to controls (8.2 ± 2.6 vs. 29.7 ± 6.4, *P* = 0.00 and 22.6 ± 5.2 vs. 55.3 ± 9.4, *P* = 0.00) respectively \[[Table 4](#T4){ref-type="table"}\].

###### 

End-points

![](IJCCM-22-168-g005)

The evolution of hemodynamic parameters to improvement was rapid in MB group compared to controls . There was a statistical significant difference in CI, MAP, SVRI, lactate, and VIS between MB group and control group as rapid as 8--12 h after admission which equals almost 4--8 h after the start of MB. On the other hand, the control group took between 24 and 36 h to show adequate improvement to the degree of insignificance compared to MB group \[Figure [2a](#F2){ref-type="fig"}--[e](#F2){ref-type="fig"}\].

![Evolution of hemodynamics over time in both groups. a: CI, cardiac index; b:MAP, mean arterial pressure; c: SVRI, systemic vascular resistance index; d: VIS, vasoactive inotropic score; e: lactate. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01](IJCCM-22-168-g006){#F2}

Mortality at day 30 was statistically significant higher in controls compared to MB (1 patient \[3.6%\] vs. 6 patients \[21.4%\], long rank *P* = 0.04) \[[Figure 3](#F3){ref-type="fig"}\].

![Kaplan--Meier curve for survival in two groups](IJCCM-22-168-g007){#F3}

ICU, hospital LOS, and incidence of new renal failure not requiring dialysis were statistically significant higher in control grouped compared to MB \[[Table 4](#T4){ref-type="table"}\]. Duration of MV was less in MB patients, however, did not reach statistical significance. Other ICU acquired complications showed no statistical significant different between patients.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

VS is a well-known complication following cardiac surgery.\[[@ref1]\] In this study, we have demonstrated that the treatment of VS after CPB with intravenous MB showed a significantly quicker recovery to normal hemodynamics, shorter duration of vasopressor infusions, less incidence of renal complications, shorter LOS and less 30-days mortality.

Duration of VS is another factor that adds to the poor outcome. Persistence of the VS for more than 48 h is associated with worse prognosis or even death.\[[@ref25]\] Mehaffey *et al*.\[[@ref26]\] showed that the early administration of MB improves survival and reduces the risk-adjusted rate of major adverse events for VS after cardiac operation. In this review, the time between the admission and the start of MB was around 4 h and the Ti was 4--5 h. Even time till complete discontinuation of vasopressors in MB group was less than Ti in the control group (22.6 ± 5.2 vs. 29.7 ± 6.4). We think that this has resulted in a less LOS, renal impairment, and mortality in MB-treated patients.

The favorable effect of MB on SVR and CI in shock situations has been established. Earlier, Leyh *et al*.\[[@ref11]\] assessed the clinical effect of MB therapy for norepinephrine-refractory vasoplegia after CPB showing an increase in SVR and a decrease in norepinephrine dosage. However, unlike Leyh *et al*.\[[@ref11]\] this work shows the clear improvement over time of different hemodynamic parameters, lactate (as a marker of restoration of peripheral circulation), and inotropic support compared to a control group.

Levin *et al*.\[[@ref12]\] confirmed the effectiveness of MB treatment in reducing postoperative morbidity and mortality and showed no incidence of complications in VS patients treated with MB in 2 h. Similarly, the current study shows a significant decrease in mortality after 30 days (3.6% in MB group vs. 21.4% in control), length of ICU (7 ± 1.4 in MB group vs. 12.4 ± 3.7 in control), and in length of hospital stay (10.9 ± 3.2 in MB group vs. 19.5 ± 2.4 in control). This also goes in agreement with results of MB prophylactic administration in the preoperative period for patients at risk of having vasoplegia with CPB.\[[@ref13]\] In contrast, Weiner *et al*.\[[@ref15]\] in their retrospective study, demonstrated an increase in mortality in patients receiving MB. However, patients who received MB were sicker than those who did not.\[[@ref15]\] Moreover, those patients\[[@ref15]\] were sicker than those of other studies.\[[@ref13][@ref12]\] They had higher CBP times (194 min), and higher Euro-score II (11) compared to an average of 7.6 in the current study. The time when MB was used\[[@ref15]\] was variable in relation to the proposed window of opportunity\[[@ref27][@ref28]\] and even after matching patients, this can still lead to difference in morbidity. Weiner *et al*.\[[@ref15]\] also suggested that MB improves macrocirculation while having a detrimental effect on microcirculation; however, studying lactate levels in our patients, showed a significant drop in the MB group after 12 h from admission, and a normal lactate levels 18 h after admission onward \[[Figure 2e](#F2){ref-type="fig"}\]. This goes in agreement with results of Maslow *et al*.\[[@ref14]\] in their prospective study of MB effect when given during CPB in patients receiving ACEI.

Higher MAP at the time of drug administration and surgery with deep hypothermic circulatory arrest have been suggested by Mazzeffi *et al*.\[[@ref29]\] as a predictor of greater MB response. This was not the case in our MB-treated patients who had a lower MAP on admission compared to the control group, (43.9 ± 5.9 vs. 47.4 ± 6.8, *P* = 0.3); however, they had a better outcomes.

![](IJCCM-22-168-g008)

As for the incidence of postoperative ICU complications in the current study, there was no advantage between two groups except for a significant decrease in renal complications within MB group. Complications related to MB administration have been described. This includes decreased mesenteric perfusion with high dose (7 mg/kg),\[[@ref30]\] slight increase in serum glutamic pyruvic transaminase has been observed and found to be quickly resolving.\[[@ref13]\] Increase in pulmonary vascular pressure/resistance, and deterioration in gas exchange can occur following MB in large doses.\[[@ref31]\] Our results shows a slight nonsignificant increase in pulmonary artery pressure associated with a slight decrease in PaO~2~/FiO~2~ ratio; however, MB patients had lower ventilation duration, less ARDS incidence, and lower incidence of reintubation.

The current study has limitations. First, the retrospective nature of the study means that findings may be affected by unmeasured confounders and mostly should be viewed as associative. Second, the control group was chosen from an older time window which could have added more confounding factors; however, propensity score matching controlled this issue. Third, no clear definition for hemodynamic improvement, we could not use crude target values for MAP, CVP, CI, and SVRI to represent improvement nor percentage of improvement, mainly because differences between the patients, for example, rise of MAP from 40 to 48 is 20% improvement but is it considered a target improvement and discontinue MB? Hence, we based mainly on the reduction of VIS to \<50% of the maximum as an indicator of improvement of VS and hence starting discontinuation of MB.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

MB for treatment of VS postcardiac surgery showed rapid restoration of hemodynamics, decreased need for vasopressors, significantly less mortality, renal impairment, and LOS. The relatively early utilization of MB might have influenced our outcomes. The recent controversies regarding morbidity and mortality with MB require more large randomized controlled trials to explore the impact on outcome.
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